Phase 1 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been confirmed by tissue or cell testing to have high-grade abnormal cells (dysplasia) or cervical cancer, specifically of the squamous cell, adenocarcinoma, or adenosquamous cell carcinoma types
- People whose condition is being managed with one of these procedures: a LEEP (a procedure to remove abnormal cervical tissue using a wire loop), a cone biopsy (CKC), a hysterectomy (removal of the uterus), or a combination of chemotherapy and radiation
- People aged 18 years or older
- People with normal liver function, as confirmed by standard blood tests
- People who speak English
- People who are able to understand the trial and are willing to sign a consent form
Who may not be able to join:
- People with active liver disease, including primary biliary cirrhosis or unexplained abnormal liver blood test results
- People with severe kidney impairment or who are on dialysis for end-stage kidney disease
- People with pre-existing gallbladder problems, including active gallstones
- People with a known allergy or sensitivity to fenofibrate or fenofibric acid (a type of medication)
- People who are pregnant or breastfeeding, due to unknown risks to the baby or infant — note that the trial site screens people who could potentially become pregnant for pregnancy before any procedures and again before treatment begins
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lindsay Ferguson, MD, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Phone: 216-844-3954
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in p53 levels; Change in tumor metabolic status
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.